It has recently reported that pemafibrate was superior to omega-3 fatty acid ethyl in not only lowering ALT, the primary endpoint, but also improving other liver enzymes, lipid profiles, and hepatic fibrosis biomarkers in the PORTRAIT study, which prospectively compared the effects of pemafibrate and omega-3 fatty acid ethyl on liver function in patients with hypertriglyceridemia complicated by MASLD (37). Here, GPT is linked to hypertriglyceridemia.